This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Todd Maloney, PhD
Executive Director, Synthetic Molecule Design and Development at Eli Lilly & Co


Todd D. Maloney earned his B.S. in Chemistry in 1996 from the State University of New York at Oswego, and his Ph.D. in Chemistry in 2001 from the University at Buffalo, The State University of New York. He started his career in 2001 with Pfizer Global Research and Development in Ann Arbor, MI. While at Pfizer he was a member of the Chemical R&D and Analytical Sciences R&D organizations, where he was involved in early phase analytical development, automation technologies, and in-silico method development strategies for pharmaceutical analysis. In 2007 he joined Eli Lilly and Company and is currently an Executive Director in the Synthetic Molecule Design and Development group where he leads teams developing process analytical technologies and integrated process control strategies for synthetic oligonucleotides, peptides, and small molecules.

Agenda Sessions

  • Characterization of Synthetic Oligonucleotides Leveraging Multiple Modes and Dimensions of Liquid Chromatography and Mass Spectrometry